BlackRock Inc. increased its holdings in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 79.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,559 shares of the company’s stock after acquiring an additional 3,338 shares during the period. BlackRock Inc.’s holdings in Taro Pharmaceutical Industries were worth $743,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. Brandes Investment Partners LP grew its holdings in shares of Taro Pharmaceutical Industries by 2.1% in the third quarter. Brandes Investment Partners LP now owns 44,851 shares of the company’s stock valued at $6,585,000 after acquiring an additional 930 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Taro Pharmaceutical Industries by 52.5% during the third quarter. Bank of New York Mellon Corp now owns 30,676 shares of the company’s stock valued at $3,015,000 after purchasing an additional 10,567 shares during the period. Jupiter Asset Management Ltd. grew its holdings in Taro Pharmaceutical Industries by 43.1% during the third quarter. Jupiter Asset Management Ltd. now owns 58,509 shares of the company’s stock valued at $5,724,000 after purchasing an additional 17,617 shares during the period. Highstreet Asset Management Inc. grew its holdings in Taro Pharmaceutical Industries by 11.0% during the third quarter. Highstreet Asset Management Inc. now owns 5,943 shares of the company’s stock valued at $584,000 after purchasing an additional 588 shares during the period. Finally, LSV Asset Management bought a new position in Taro Pharmaceutical Industries during the third quarter valued at $327,000. 10.17% of the stock is owned by institutional investors.
Several brokerages have weighed in on TARO. ValuEngine lowered Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Friday, December 21st. HC Wainwright reissued a “buy” rating and set a $115.00 price objective on shares of Taro Pharmaceutical Industries in a report on Monday, December 10th. Finally, Zacks Investment Research raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Friday.
TRADEMARK VIOLATION WARNING: This story was posted by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://weekherald.com/2019/02/12/taro-pharmaceutical-industries-ltd-taro-stake-boosted-by-blackrock-inc.html.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: How accurate is the Rule of 72?
Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.